Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of
Actinium is showing early results from a new cancer treatment experiment. When a company shares promising early data, watch to see if the treatment keeps working as it grows.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.